Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21526328 | 0.84 | SIRT6 (0.64) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL29985984 | 0.82 | MEN1 (0.54) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL17373705 | 0.81 | MAPT (0.59) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL25200165 | 0.81 | MAPT (0.59) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL6824323 | 0.81 | SIRT6 (0.56) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL4290276 | 0.81 | ESRRG (0.63) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL4290270 | 0.81 | ESRRG (0.63) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL22175056 | 0.80 | SIRT6 (0.63) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL17047527 | 0.80 | MAPT (0.53) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL7986410 | 0.79 | SIRT6 (0.66) | SIRT6ADRB1MAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024155112-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | UPPTHERA, INC. (KR) | 2024-07-25 | — | — | WO | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022251224-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2021255212-A1 | BRAF DEGRADERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | SIRT6 3474/4885ADRB1 797/4885MAPT 4613/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | SIRT6 1837/4885ADRB1 4475/4885MAPT 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.